Trading

FDA Clears Teva’s Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

Summary

Teva Pharmaceutical Industries has received FDA approval for its sublingual film, IGALMI, enabling at-home treatment for acute agitation related to specific mental health conditions. This regulatory decision marks a first-of-its-kind authorization allowing adult patients to manage these episodes independently outside of a medical facility.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use. This regulatory decision makes IGALMI the first FDA-approved treatment that adults can use at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. IGALMI (dexmedetomidine) sublingual film is a prescription…

Source: Read the full story at Top Stories Feed

Follow Tech & Money Press for daily watchlists and market news

XFacebookInstagramTikTokYouTube
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.
About UsContactPrivacy PolicyDisclaimer
Not financial advice. Curated headlines link to their original publishers.